Marleen K.
- Country
- The Netherlands
- Department
- Medical Oncology
Research Overview
- Phase III Trial of BNT327 plus Combination Chemotherapy versus Placebo plus Chemotherapy in Patients with Previously Untreated Metastatic or Locally Recurrent Triple-Negative Breast Cancer
- Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy
- Evaluation of Atezolizumab, Tiragolumab, and Ipilimumab in Advanced Triple Negative Breast Cancer: TONIC-3 Trial
Data & Insights
Has run more than one trial at 79 of 235 partner sites.
Specializations
Triple Negative Breast Cancer Research
The investigator specializes in developing innovative treatments for triple negative breast cancer (TNBC), with particular emphasis on metastatic disease management. Their work explores various immunotherapy approaches, including the implementation of different immune response induction treatments.
- Advanced TNBC Treatment Strategies
- Immune Response Modulation
- Metastatic Disease Management
Immunotherapy Innovation
Key research focuses on immune checkpoint blockade therapies, particularly involving nivolumab and its combinations. The investigator studies pre-operative immunotherapy approaches and novel immunomodulatory strategies for breast cancer treatment.
- Checkpoint Inhibitor Therapy
- Combination Immunotherapy
- Preoperative Treatment Approaches
Specialized Breast Cancer Treatment
The investigator conducts research in various breast cancer subtypes, including HER2-positive breast cancer and hormone receptor positive disease. Their work extends to oligometastatic disease and novel therapeutic combinations.
- HER2-Positive Disease Management
- Hormone Receptor Positive Cancer
- Biomarker-Driven Therapies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.